Steve Elms Purchases 7,000 Shares of ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics Inc (NASDAQ:ADMA) Director Steve Elms bought 7,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

ADMA Biologics Trading Up 0.1%

Shares of ADMA stock opened at $15.83 on Wednesday. ADMA Biologics Inc has a 1 year low of $13.76 and a 1 year high of $25.67. The firm has a market capitalization of $3.77 billion, a PE ratio of 26.38 and a beta of 0.51. The stock has a fifty day moving average of $16.81 and a two-hundred day moving average of $16.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, meeting analysts’ consensus estimates of $0.20. The company had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period last year, the company earned $0.46 earnings per share. As a group, research analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds have recently made changes to their positions in ADMA. Quadrant Capital Group LLC raised its holdings in shares of ADMA Biologics by 3.9% in the 2nd quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 629 shares in the last quarter. Lido Advisors LLC grew its position in ADMA Biologics by 3.8% in the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock worth $312,000 after buying an additional 629 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in ADMA Biologics by 11.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock worth $117,000 after buying an additional 634 shares during the last quarter. Cim LLC increased its holdings in shares of ADMA Biologics by 0.7% in the third quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock valued at $1,341,000 after buying an additional 665 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in shares of ADMA Biologics by 28.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 700 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Ratings Changes

ADMA has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Buy” and a consensus price target of $32.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.